IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: While this may be detrimental in some cases, complete molecular remission has been observed in several cases of chronic myelogenous leukemia (CML) where IFNα pre-treatment was followed by imatinib mesylate (144), suggesting that IFNα may induce CML stem cell exit from dormancy and subsequent sensitization to growth factor withdrawal.